Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


US Judge Dismisses Gautam Adani Criminal Charges
OpenAI Executive Brad Lightcap to Leave for New AI Venture
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes
Airbus Joins Air India A320 Altitude Drop Probe
SpaceX Shares Surge as Wall Street Backs AI Growth Potential
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations
ASX Faces Legal Action Over Failed Blockchain CHESS Project
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast
ADNOC Gas Targets Up to $4B Profit in 2026
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 



